PHOTOCURE ANNOUNCES BIOSYENT AS EXCLUSIVE PARTNER FOR CYSVIEW® IN CANADA

Oslo, Norway, 19 August, 2015: Photocure ASA (OSE: PHO), a specialty
pharmaceutical company focused on photodynamic technologies, announces today the
appointment of BioSyent Pharma Inc. as their exclusive distributor for the
commercialization of Cysview in Canada. Cysview(®)/Hexvix(®) is Photocure's
flagship product to aid in the diagnosis and management of bladder cancer.

Under the terms of the agreement, Photocure will receive up to USD 1,000,000 in
milestone payments for the rights to Cysview in the territory, which includes
USD 650,000 upon signing of the agreement.

BioSyent Pharma will fund all costs related to the launch and commercialization
of Cysview, which was approved by Health Canada in January 2015. The market
potential in the territory is estimated to be similar to the potential in the
Nordics, where Photocure commercializes Hexvix with its own sales team.

Kjetil Hestdal, President & CEO of Photocure, said: "We are pleased to have
secured BioSyent Pharma as our new commercialization partner in Canada with
their market position within urology and their strong and experienced team. We
are happy to report that Hexvix/Cysview commercialization is progressing well
and we continue to expand into new territories to ensure patients and urologists
have access to the most optimal treatment for the diagnosis and management of
bladder cancer."

René Goehrum, President & CEO of BioSyent, said: "We are delighted to partner
with Photocure to commercialize an innovative product such as Cysview for
Canadian patients and health care professionals. This product has clearly
demonstrated that it can improve patient lives. Furthermore, Cysview fits well
with our existing urology business."



For further information, please contact:

Photocure

President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email: kh@photocure.no

CFO Erik Dahl
Tel: +47 450 55 000, Email: ed@photocure.no



About Photocure ASA

Photocure ASA, headquartered in Oslo, Norway, is a specialty pharmaceutical
company and world leader in photodynamic technology. Based on our unique
proprietary Photocure Technology(®) platform, Photocure develops and
commercializes highly selective and effective solutions in disease areas with
high unmet medical need, such as bladder cancer, HPV and precancerous cervical
lesions, colorectal cancer and skin conditions. Our aim is to provide solutions
that can improve health outcomes for patients worldwide. Photocure is listed on
the Oslo Stock Exchange (OSE: PHO). Information about Photocure is available at
www.photocure.com.

About Hexvix(®)/Cysview(®)

Hexvix(®)/Cysview(®) (hexaminolevulinate hydro-chloride) is an innovative
breakthrough technology in the diagnosis and management of non-muscle-invasive
bladder cancer. It is designed to selectively target malignant cells in the
bladder and induce fluorescence during a cystoscopic procedure using a blue-
light enabled cystoscope. Using Hexvix(®)/Cysview(®) as an adjunct to standard
white-light cystoscopy enables the urologist to better detect and remove
lesions, leading to a reduced risk of recurrence. Hexvix(®)/Cysview(®) is
approved in Europe, Canada and the USA.

About BioSyent Pharma Inc


Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent
is a profitable growth oriented specialty pharmaceutical company which searches
the globe to in-license or acquire innovative pharmaceutical products that have
been successfully developed, are safe and effective, and have a proven track
record of improving the lives of patients and supporting the healthcare
professionals that treat them. Once a product of interest has been found,
BioSyent then acquires the exclusive rights to the product and manages it
through the Canadian governmental regulatory approval process. Once approved,
BioSyent markets the product throughout Canada.



All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)



[HUG#1946403]